Molecular basis for activation of lecithin:cholesterol acyltransferase by a compound that increases HDL cholesterol
Lecithin:cholesterol acyltransferase (LCAT) and LCAT-activating compounds are being investigated as treatments for coronary heart disease (CHD) and familial LCAT deficiency (FLD). Herein we report the crystal structure of human LCAT in complex with a potent piperidinylpyrazolopyridine activator and...
Main Authors: | Kelly A Manthei, Shyh-Ming Yang, Bolormaa Baljinnyam, Louise Chang, Alisa Glukhova, Wenmin Yuan, Lita A Freeman, David J Maloney, Anna Schwendeman, Alan T Remaley, Ajit Jadhav, John JG Tesmer |
---|---|
Format: | Article |
Language: | English |
Published: |
eLife Sciences Publications Ltd
2018-11-01
|
Series: | eLife |
Subjects: | |
Online Access: | https://elifesciences.org/articles/41604 |
Similar Items
-
Effects of natural mutations in lecithin:cholesterol acyltransferase on the enzyme structure and activity
by: F. Peelman, et al.
Published: (1999-01-01) -
A systematic review of the natural history and biomarkers of primary lecithin:cholesterol acyltransferase deficiency
by: Cecilia Vitali, et al.
Published: (2022-03-01) -
High-Density Lipoprotein, Lecithin: Cholesterol Acyltransferase, and Atherosclerosis
by: Alice Ossoli, et al.
Published: (2016-06-01) -
Evidence that lipid hydroperoxides inhibit plasma lecithin:cholesterol acyltransferase activity
by: John K. Bielicki, et al.
Published: (1999-05-01) -
Familial lecithin-cholesterol acyltransferase (LCAT) deficiency; a differential of proteinuria
by: Mohammed Mahdi Althaf, et al.
Published: (2015-01-01)